Eltrombopag for the treatment of refractory acquired pure red cell aplasia
- Author:
Xiao-qing LIU
1
;
Lang CHEN
1
;
Yao HE
1
;
Run ZHANG
1
;
Rui-nan LU
1
;
Jian-fu ZHANG
1
;
Ming HONG
1
;
Guang-sheng HE
1
;
Jian-yong LI
1
Author Information
- Publication Type:Journal Article
- Keywords: eltrombopag; refractory; pure red cell aplasia
- From: Chinese Journal of Practical Internal Medicine 2019;39(09):805-808
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To investigate the efficacy of eltrombopag in the treatment of refractory acquired pure red cell aplasia(PRCA). METHODS: Three patients with refractory acquired PRCA treated in the First Affiliated Hospital of Nanjing Medical University/Jiangsu Province Hospital from March 2018 to May 2019 were treated with eltrombopag(75 mg/d). The clinical data were collected for evaluating efficacy and tolerance. RESULTS: The erythrocyte count(P=0.039), hemoglobin concentration(P=0.018) and reticulocyte percentage(P=0.046) in 3 patients were significantly higher than those before treatment. The platelet count was higher than that before treatment(P=0.024). The leukocyte count and absolute neutrophil count increased in 2 patients, and decreased in 1 patient, but still remained in the normal range(P=0.924; P =0.565). Total bilirubin(TBIL) and direct bilirubin(DBIL) increased in 1 case; alanine aminotransferase(ALT), aspartate aminotransferase(AST) and serum creatinine(Scr) increased in 1 case; palpitation occurred in 1 case. All the side effects were alleviated after symptomatic treatment. CONCLUSION: Eltrombopag has certain efficacy and good tolerance in the treatment of refractory acquired PRCA, which is worthy of further exploration.
